Mana Therapeutics
Innovative cell therapies enhancing cancer treatment efficacy, safety, and accessibility.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $7.0m | Series A | |
| Total Funding | 000k | ||
MANA Therapeutics is a biotechnology company focused on developing advanced cell therapies to treat a wide range of liquid and solid tumors. The company operates in the immuno-oncology market, targeting cancer patients who require more effective and safer treatment options. MANA's business model revolves around leveraging proprietary research and clinical trials to create commercial products that improve patient outcomes. The company generates revenue through the development and commercialization of these unique cellular therapies, which are licensed from leading research institutions like the National Hospital CNH and Johns Hopkins Medical Center. MANA's clients include healthcare providers, hospitals, and cancer treatment centers that seek cutting-edge solutions for their patients. Founded in November 2018, MANA Therapeutics is driven by a mission to make advanced cancer treatments more accessible and effective, inspired by the Maori concept of 'mana,' which emphasizes leadership and care for others.
Keywords: cell therapies, cancer treatment, immuno-oncology, biotechnology, clinical trials, proprietary research, healthcare providers, tumor treatment, patient outcomes, commercial products.